CDP-choline treatment in amphetamine type stimulant-using adolescents

CDP-胆碱治疗安非他明类兴奋剂青少年

• 批准号: 9468363
• 负责人: In Kyoon Lyoo
• 金额: $ 46.28万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-15 至 2020-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9468363
• 关键词: Abstinence; Adolescent; Adult; Amphetamines; Attention; Award; Behavior; Behavioral; Biological; Brain; Brain region; Choline; Clinical; Clinical Trials; Cognitive; Cognitive Therapy; Cognitive deficits; Collaborations; Cytidine; Cytidine Diphosphate Choline; Data; Diffusion Magnetic Resonance Imaging; Diphosphates; Drug Addiction; Drug Prescriptions; Drug abuse; Executive Dysfunction; Food; Funding; Health; High School Student; Human; Image; Image Analysis; Institutes; International; Knowledge; Membrane; Methamphetamine; Molecular; Molecular Target; Monitor; Multimodal Imaging; NIH Program Announcements; Neurons; Neuropsychological Tests; Outcome Measure; Participant; Pathway Analysis; Patient Self-Report; Performance; Pharmaceutical Preparations; Phospholipids; Placebos; Population; Prefrontal Cortex; Property; Randomized; Reporting; Research; Research Proposals; Resources; Scientist; Site; South Korea; System; Thick; Treatment Efficacy; Universities; Urine; Utah; amphetamine use; base; brain abnormalities; cell injury; college; double-blind placebo controlled trial; executive function; global health; gray matter; improved; inorganic phosphate; magnetic resonance spectroscopic imaging; methamphetamine effect; methamphetamine use; methamphetamine user; multimodality; myelination; named group; neural circuit; neuroimaging; neurotoxicity; nonmedical use; novel; programs; public health relevance; recruit; repaired; stimulant use; success; symptomatic improvement; synthetic drug; treatment strategy; trend; white matter

 DESCRIPTION (provided by applicant): The increased use of amphetamine-type stimulants (ATS), which refer to the group of stimulants including methamphetamine (MA) and amphetamine, has become a major global health problem in recent years. There is also an increasing concern about the high rate of the non-medical use of prescription stimulants among adolescents. In this competing renewal of DA024070, an international collaborative study aimed to determine the effects of MA on the developing brain, we propose to extend our studies in ATS-using adolescents to evaluate a novel treatment strategy for this population. On the basis of preliminary findings identifying adolescent-specific brain and cognitive vulnerability to stimulant exposure and the neuroprotective properties of cytidine-5'-diphosphate choline (CDP-choline), we propose to conduct a 12-week, randomized, double-blind, placebo-controlled trial of CDP-choline in ATS-using adolescents. As outcome measures, multi-level assessments will be performed at molecular, neural circuitry, cognitive, and clinical levels. It will be determined whether CDP-choline administration, compared to placebo administration, will 1) repair ATS-induced neural cell damage within the target brain regions, which will be assessed using multinuclear magnetic resonance spectroscopic imaging, 2) improve cognitive deficits and normalize the relevant target neural circuits, which will be assessed using neuropsychological tests and multimodal imaging analyses including cortical thickness analysis, diffusion tensor imaging analysis, and network analysis, and 3) reduce ATS-taking behaviors, which will be assessed using a combination of urine monitoring and self-report of ATS use. This study will demonstrate that CDP-choline engages the treatment target and thereby provides clinical benefits to ATS-using adolescents. In the context of the unique opportunity to recruit a special population, such as ATS-using adolescents, in Seoul, South Korea, this project will be performed based on the international collaboration between Perry F. Renshaw at the Brain Institute, the University of Utah, UT, USA and In Kyoon Lyoo at the Ewha Brain Institute, Ewha W. University, Seoul, South Korea. We believe that this research proposal is highly responsive to the International Research Collaboration on Drug Abuse and Addiction Research Program Announcement (PA-12- 040) that encourages the utilization of unique resources or subject populations which would otherwise be difficult to access domestically. As is also acknowledged in the '2007 Distinguished International Scientist Collaboration Award' and '2008 International Program Award for Excellence [Collaborative Research]', our well established collaboration will contribute to the success of this proposal.

 描述（由适用提供）：苯丙胺型刺激剂的使用增加（ATS），它是指近年来的主要全球健康问题，包括甲基苯丙胺（MA）和苯丙胺等兴奋剂。人们对青少年中处方兴奋剂的非医学使用率也越来越担心。在DA024070的这种竞争续约中，一项国际合作研究旨在确定MA对发展中大脑的影响，我们建议扩展我们在使用ATS的青少年中的研究，以评估该人群的新型治疗策略。根据鉴定青少年特异性大脑的初步发现和刺激性暴露的认知脆弱性以及细胞丁烷-5'-二磷酸胆碱（CDP-胆碱）的神经保护特性，我们建议进行12周的12周，随机，随机，双蓝色的，安慰剂，安慰剂控制的CDP-CHP-CHONERES-AD-AD-AD-AD-AD-ADCECCC-AD-ATIS ATISADCC。作为结果度量，将在分子，神经回路，认知和临床水平上进行多层次评估。 It will be determined whether CDP-choline administration, compared to placebo administration, will 1) repair ATS-induced neural cell damage within the target brain regions, which will be assessed using multinuclear magnetic resonance spectroscopic imaging, 2) improve cognitive defines and normalize the relevant target neural circuits, which will be assessed using neuropsychological tests and multimodal imaging analysis including cortical thickness analysis, diffusion tensor成像分析和网络分析以及3）减少ATS的行为，将使用尿液监测和ATS使用自我报告的组合来评估。这项研究将表明CDP-胆碱与治疗靶标有关，从而为使用ATS的青少年提供临床益处。在招募特殊人群的独特机会（例如使用ATS的青少年）的背景下，将根据韩国首尔的首尔，根据犹他州犹他州，犹他大学，美国犹他大学和Ewha Brain Institute的Kyoon Lyoo在EWHA W. Wha W. University，ew. University，Seoul，Seoul，Seoul，Seoul，Seoul，Seoulea，Seoula，Seoul，Seoul，Seoulion Institute和Kyoon Lyoo的佩里·F·Renshaw（Perry F. Renshaw）之间进行国际合作。我们认为，这项研究建议对国际药物滥用和成瘾研究计划公告（PA-12-040）的国际研究合作具有很高的反应，该研究鼓励利用独特的资源或主题人群，否则很难在国内访问。正如“ 2007年杰出国际科学家合作奖”和“ 2008年国际计划卓越计划[合作研究]奖）也所承认的那样，我们建立的合作将有助于该提案的成功。